Until recently, to analyze many mRNAs simultaneously, scientists had to grind cells to a pulp, which left them unable to pinpoint those mRNAs within the cell. Developed by a team at the Wyss and Harvard Medical School, FISSEQ allows scientists to pinpoint thousands of mRNAs and other types of RNAs at once in intact cells, and stands to revolutionize clinical diagnostics and drug discovery.
DISRUPTIVE – the podcast from Harvard’s Wyss Institute for Biologically Inspired Engineering.
We’re learning to take advantage of properties of DNA that have served nature well- but in ways nature may have never pursued. We build with it. We tap its capacity to carry information to enhance our ability to explore the inner life of cells.
In this episode, Wyss faculty members William Shih, Wesley Wong and Peng Yin share what it’s like being on the frontier of science, explain how and why they program DNA, and consider potential applications of their work.
I’m excited to offer the first episode of DISRUPTIVE, my new monthly podcast series produced with Harvard’s Wyss Institute for Biologically Inspired Engineering. The mission of the Wyss Institute is to: Transform healthcare, industry, and the environment by emulating the way nature builds, with a focus on technology development and its translation into products and therapies that will have an impact on the world in which we live. Their work is disruptive not only in terms of science but also in how they stretch the usual boundaries of academia.
In this inaugural episode, Wyss core faculty members Pamela Silver and George Church explain how, with today’s technology breakthroughs, modifications to an organism’s genome can be conducted more cheaply, efficiently, and effectively than ever before. Researchers are programming microbes to treat wastewater, generate electricity, manufacture jet fuel, create hemoglobin, and fabricate new drugs. What sounds like science fiction to most of us might be a reality in our lifetimes: the ability to build diagnostic tools that live within our bodies, find ways to eradicate malaria from mosquito lines, or possibly even make genetic improvements in humans that are passed down to future generations. Silver and Church discuss both the high-impact benefits of their work as well as their commitment to the prevention of unintended consequences in this new age of genetic engineering.
Welcome to DISRUPTIVE the podcast from Harvard’s Wyss Institute for Biologically Inspired Engineering.
In this episode of DISRUPTIVE, we will focus on a cancer vaccine and hydrogel drug depots – both being developed by Wyss Founding Core Faculty Member, DAVE MOONEY. Mooney says the human immune system is the most efficient weapon on the planet to fight disease. Cancer, however, resists treatment and cure by evading the immune system. Unlike bacterial cells or viruses, cancer cells belong in the body, but are simply mutated and misplaced. Scientists have been trying to develop vaccines that provoke the immune system to recognize cancer cells as foreign and attack them. The approach developed by Mooney’s group, in which they reprogram immune cells from inside the body using implantable biomaterials, appears simpler and more effective than other cancer vaccines currently in clinical trials. In one study, 50% of mice treated with two doses of the vaccine — mice that would have otherwise died from melanoma within about 25 days — showed complete tumor regression. On a second front, when it comes to delivering drugs or protein-based therapeutics, doctors often give patients pills or inject the drug into their bloodstream. Both are inefficient methods for delivering effective doses to targeted tissues. Mooney and his team at Wyss are taking a new approach using biocompatible and biodegradable hydrogels. They’ve developed a gel-based sponge that can be molded to any shape, loaded with drugs or stem cells, compressed to a fraction of its size, and delivered via injection. Once inside the body, it pops back to its original shape, gradually releases its payload, and safely degrades. After we explore both of these exciting projects with Mooney, we take a closer look at the process of translation of hydrogel technology into products and therapies with Chris Gemmiti, a business development lead at Wyss.